Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Mar 29:4:7.
doi: 10.1038/s41392-019-0041-1. eCollection 2019.

Targeting NR4As, a new strategy to fine-tune CAR-T cells against solid tumors

Feng Li  1 , Yi Zhang  1
Affiliations
Comment

Targeting NR4As, a new strategy to fine-tune CAR-T cells against solid tumors

Feng Li et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Strategies to augment chimeric antigen receptor T (CAR-T) cell activity in treating solid tumors. Dysfunction of CAR-T cells is related to many intrinsic and extrinsic factors (right). Maintenance of the proliferative T cells and reversion of the inhibition signals are reasonably needed to sustain CAR-T cell function within the tumor (left). Manipulation of the genes that exacerbate T-cell exhaustion is also effective in improving the efficacy of CAR-T cell therapy (left)
See this image and copyright information in PMC

Comment on

References

    1. Chen Joyce, López-Moyado Isaac F., Seo Hyungseok, Lio Chan-Wang J., Hempleman Laura J., Sekiya Takashi, Yoshimura Akihiko, Scott-Browne James P., Rao Anjana. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567(7749):530–534. doi: 10.1038/s41586-019-0985-x. - DOI - PMC - PubMed
    1. June CH, Sadelain M. Chimeric antigen receptor therapy. N. Engl. J. Med. 2018;379:64–73. doi: 10.1056/NEJMra1706169. - DOI - PMC - PubMed
    1. Cherkassky L, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 2016;126:3130–3144. doi: 10.1172/JCI83092. - DOI - PMC - PubMed
    1. Rafiq S, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 2018;36:847–856. doi: 10.1038/nbt.4195. - DOI - PMC - PubMed
    1. Sukumaran S, et al. Enhancing the potency and specificity of engineered T cells for cancer treatment. Cancer Discov. 2018;8:972–987. doi: 10.1158/2159-8290.CD-17-1298. - DOI - PMC - PubMed

Substances